Compare National Beverage Corp. (FIZZ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Moderna, Inc. — how do they compare? National Beverage Corp. trades at $30.56 (market cap $2.89B), while Moderna, Inc. trades at $206.43 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 27.2× National Beverage Corp.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Moderna, Inc. for 59 Days on average.
| FIZZ | MRNA | |
|---|---|---|
Market Cap | $2.89B | $78.65B |
Volume | 553,950 | 37,373,437 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $203.46 |
52-Week Low | $29.20 | $22.36 |
Typical Hold Time | 33 Days | 59 Days |
Enterprise Value | $2.84B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $29.60, down 1.4% with bearish technical signals. The company reported stagnant $1.2B revenue but improved net margins to 15.55% in 2025. Recent earnings misses and a $3.25 special dividend highlight mixed performance. Technical indicators show strong bearish momentum with support at $29 and resistance at $30.
Outlook remains challenged by margin pressure and growth stagnation. While strong profitability metrics (40% ROE) provide support, analyst sentiment is cautious with 50% sell ratings. Key risks include competitive pressures and input cost inflation affecting gross margins.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
